Profile
Sector:
HealthcareCountry:
IsraelIPO:
07 January 2013Website:
http://www.redhillbio.comNext earnings report:
05 July 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:35:19 GMTDividend
Analysts recommendations
Institutional Ownership
RDHL Latest News
RedHill Biopharma Ltd. American depositary receipts RDHL, +8.20% climbed 10% premarket on Wednesday after the company said two of its experimental drugs, when individually combined with remdesivir, showed promise in combating the Ebola virus.
Redhill Biopharma (NASDAQ: RDHL ) stock is sliding lower on Thursday but only after the company's shares come off of a recent rally. Shares of RDHL stock saw major gains earlier in the week.
RedHill Biopharma Ltd (NASDAQ: RDHL) just received an exclusive licence for the commercialisation of Talicia. The drug is used to treat Helicobacter Pylori infections, commonly known as H- Pylori.
Amid a slow start to the new week, specialty drug developer RedHill Biopharma (NASDAQ: RDHL ) dramatically enlivened the mood, skyrocketing over 180% during the early afternoon session. Catapulting sentiment was regulatory approval for Talicia, a therapeutic designed to target helicobacter pylori (H.
RedHill Biopharma Ltd.'s stock RDHL, +1.65% soared 10% premarket after the company said it has received a further $1.7 million in U.S. government funding for its partner, Apogee, to develop a treatment for gastrointestinal acute radiation syndrome.
What type of business is RedHill Biopharma?
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
What sector is RedHill Biopharma in?
RedHill Biopharma is in the Healthcare sector
What industry is RedHill Biopharma in?
RedHill Biopharma is in the Drug Manufacturers - Specialty & Generic industry
What country is RedHill Biopharma from?
RedHill Biopharma is headquartered in Israel
When did RedHill Biopharma go public?
RedHill Biopharma initial public offering (IPO) was on 07 January 2013
What is RedHill Biopharma website?
https://www.redhillbio.com
Is RedHill Biopharma in the S&P 500?
No, RedHill Biopharma is not included in the S&P 500 index
Is RedHill Biopharma in the NASDAQ 100?
No, RedHill Biopharma is not included in the NASDAQ 100 index
Is RedHill Biopharma in the Dow Jones?
No, RedHill Biopharma is not included in the Dow Jones index
When does RedHill Biopharma report earnings?
The next expected earnings date for RedHill Biopharma is 05 July 2024